Mammalian metabolism is highly circadian and major hormonal circuits involving nuclear hormone receptors display interlinked diurnal cycling 1,2 . However, mechanisms that logically explain the coordination of nuclear hormone receptors and the clock are poorly understood. Here we show that two circadian co-regulators, cryptochromes 1 and 2, interact with the glucocorticoid receptor in a liganddependent fashion and globally alter the transcriptional response to glucocorticoids in mouse embryonic fibroblasts: cryptochrome deficiency vastly decreases gene repression and approximately doubles the number of dexamethasone-induced genes, suggesting that cryptochromes broadly oppose glucocorticoid receptor activation and promote repression. In mice, genetic loss of cryptochrome 1 and/or 2 results in glucose intolerance and constitutively high levels of circulating corticosterone, suggesting reduced suppression of the hypothalamic-pituitary-adrenal axis coupled with increased glucocorticoid transactivation in the liver. Genomically, cryptochromes 1 and 2 associate with a glucocorticoid response element in the phosphoenolpyruvate carboxykinase 1 promoter in a hormonedependent manner, and dexamethasone-induced transcription of the phosphoenolpyruvate carboxykinase 1 gene was strikingly increased in cryptochrome-deficient livers. These results reveal a specific mechanism through which cryptochromes couple the activity of clock and receptor target genes to complex genomic circuits underpinning normal metabolic homeostasis.
Mammalian metabolism is highly circadian and major hormonal circuits involving nuclear hormone receptors display interlinked diurnal cycling 1, 2 . However, mechanisms that logically explain the coordination of nuclear hormone receptors and the clock are poorly understood. Here we show that two circadian co-regulators, cryptochromes 1 and 2, interact with the glucocorticoid receptor in a liganddependent fashion and globally alter the transcriptional response to glucocorticoids in mouse embryonic fibroblasts: cryptochrome deficiency vastly decreases gene repression and approximately doubles the number of dexamethasone-induced genes, suggesting that cryptochromes broadly oppose glucocorticoid receptor activation and promote repression. In mice, genetic loss of cryptochrome 1 and/or 2 results in glucose intolerance and constitutively high levels of circulating corticosterone, suggesting reduced suppression of the hypothalamic-pituitary-adrenal axis coupled with increased glucocorticoid transactivation in the liver. Genomically, cryptochromes 1 and 2 associate with a glucocorticoid response element in the phosphoenolpyruvate carboxykinase 1 promoter in a hormonedependent manner, and dexamethasone-induced transcription of the phosphoenolpyruvate carboxykinase 1 gene was strikingly increased in cryptochrome-deficient livers. These results reveal a specific mechanism through which cryptochromes couple the activity of clock and receptor target genes to complex genomic circuits underpinning normal metabolic homeostasis.
Glucocorticoids (cortisol in humans and corticosterone in rodents) are critical regulators of many aspects of mammalian physiology, including glucose homeostasis and immune function. These stress hormones exhibit a robust diurnal rhythm in the circulation. Synthetic glucocorticoids are widely used as anti-inflammatory drugs, but cause undesirable side effects including hyperglycaemia, insulin resistance and suppression of adrenal function. A paradox of nuclear receptor signalling is that potent agonists typically repress as many genes as they activate. The cloning of the glucocorticoid receptor 3 revealed that the same gene product mediated both agonist-induced activation and repression through dichotomous mechanisms that remain poorly understood. Ligand stimulation results in translocation of glucocorticoid receptor from the cytoplasm to the nucleus where it binds to glucocorticoid response elements (GREs) and alters the transcription of hundreds to thousands of genes. Several cofactors have been identified that mediate transcriptional activation, including the steroid receptor coactivators (SRC1-3), the histone acetyltransferases CBP/p300 and the nuclear methylase coactivator-associated arginine methyltransferase 1 (CARM1) 4 . For glucocorticoid-receptor-dependent repression, combinations of direct and indirect mechanisms have been proposed. For example, glucocorticoid receptor may 'tether' or bind to pro-inflammatory transcription factors, such as nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-kB), and 'transrepress' gene expression by interfering with their activation mechanism 5 . In addition, glucocorticoids can directly repress metabolic targets, particularly in the hypothalamic-pituitary-adrenal (HPA) axis, in a way that does not seem to require NF-kB or other inflammatory transcription factors. In this case, glucocorticoid receptor acts through direct binding to negative response elements that presumably promote recruitment of one or more hypothetical repressive cofactors.
Circadian clocks drive rhythms in physiology and behaviour that enable organisms to keep track of the time of day and to adjust their physiology to adapt to recurrent, and therefore predictable, changes in the external environment. Mammalian circadian clocks are based on a transcription and translation feedback loop. In this, a heterodimer of the transcription factors circadian locomotor output cycles kaput (CLOCK) and brain and muscle ARNT-like 1 (BMAL1) drives transcription from E-box elements, including that of their own repressors, the period (Per1, Per2 and Per3) and cryptochrome (Cry1 and Cry2) genes 2 . For many years, mammalian clocks were thought to reside solely in the hypothalamic suprachiasmatic nucleus, in which the clock is set by light signals through the retinohypothalamic tract, and from which secreted signals drive rhythms in locomotor activity. Subsequently, circadian clocks have been identified throughout mammalian peripheral organs and their timing demonstrated to be determined by metabolic cues rather than in direct response to light 6 . Several molecular mechanisms have been described that contribute to metabolic resetting of clock time in peripheral organs [7] [8] [9] .
The existence of clocks in peripheral organs and the demonstration that their timing is set by metabolic cues led to the question of whether they participate in physiological regulation that enables organisms to adapt to changing metabolic needs over the course of the day. Tissuespecific ablation of clock function demonstrated that clocks in the liver 10 and pancreas 11, 12 indeed contribute to glucose homeostasis at specific times of the day. Several studies have demonstrated that thousands of transcripts are subject to circadian regulation in myriad organs 13, 14 , and that most of this regulation is lost upon tissue-specific clock disruption 10, 15 , suggesting that rhythmic transcription of rate-limiting enzymes and transporters contributes to circadian physiological regulation 14 .
The time of peak expression for these oscillating transcripts is distributed across the day, suggesting that multiple mechanisms contribute to their diurnal regulation. In addition to cascades of rhythmically expressed transcription factors, including nuclear hormone receptors, which can be driven by clock-dependent rhythmic expression, circadian repression of subsets of target genes by the negative arm of the clock may contribute to oscillation of specific genetic programs. The direct regulation of cryptochromes by metabolic signals 7 makes them ideal potential crossover regulators for circadian and metabolic gene expression programs. Because nuclear receptors are prototypic regulators of metabolism, we examined the possibility that cryptochromes 1 (Cry1) and 2 (Cry2) might contribute to diurnal aspects of their regulatory output 1 .
We first explored whether Cry1 can interact with two nuclear hormone receptors known to modulate clock function, the retinoidrelated orphan receptors (ROR-a/b/c) and Rev-Erb-a/b. Unexpectedly, we find robust association between Cry1 and ROR-a and c but not with ROR-b or Rev-Erb-a/b though we did reproduce the reported association of PER2 with Rev-Erb-a 16 (Fig. 1a, b ). This is intriguing for two reasons: (1) ROR-a and ROR-c but not ROR-b can activate Bmal1 transcription 17 and (2) Cry1 preferentially associates with the activation (ROR) and not the repressive (Rev-Erb) arm of the pathway. Together, these results suggest that the so-called 'secondary loop' in which RORs and Rev-Erbs modulate BMAL1 transcription and are thought to make clocks more robust and accurate involves cryptochromes.
We next initiated a broader survey of nuclear hormone receptor interactions and unexpectedly discovered a robust physical association of Cry1 with the glucocorticoid and androgen receptors ( Fig. 1a ). Although Per2 can interact with some nuclear hormone receptors (such as Rev-Erb 16 ), it does not appear to bind glucocorticoid receptor ( Fig. 1c ). Further analysis reveals that Cry2 also interacts with glucocorticoid receptor ( Fig. 1d ) and that the association is stimulated by glucocorticoids ( Fig. 1e, f) . Notably, Cry1 represses the ability of glucocorticoid receptor to drive expression of a luciferase reporter from a GRE-containing promoter ( Fig. 1g ). Finally, we used a series of deletion mutants of glucocorticoid receptor to demonstrate that Cry1 interacts with the carboxy (C) terminus of glucocorticoid receptor ( Fig. 1h ), which is required for either activation or repression of transcription in response to ligand. Steroid hormones (glucocorticoids, testosterone, progesterone and aldosterone) are critical regulators of metabolic and reproductive physiology, so the possibility that they could be directly regulated by cryptochromes suggests a new mechanism by which circadian clocks modulate physiological rhythms.
To determine whether cryptochromes modulate glucocorticoidstimulated changes in transcription of endogenous genes in vivo, we analysed global changes in gene expression after glucocorticoid treatment of primary fibroblasts derived from wild-type and cry1 2/2 ; cry2 2/2 double knockout (DKO) littermate mouse embryos ( Fig. 2a ). Circadian rhythms of transcription can be synchronized by dexamethasone treatment of fibroblasts 18 . These changes are expected to be lost in Cry-deficient cells, such that a subset of both positive and negative transcriptional responses to dexamethasone will be absent. However, if cryptochromes are independently capable of repressing transcription through glucocorticoid receptor, we would expect to see a global positive shift in the transcriptional response to dexamethasone (for example, an increase in gene activation and a decrease in repression). Indeed, we found that the transcriptional response to the synthetic glucocorticoid dexamethasone was significantly more positive in cryptochrome-deficient cells: 205 more genes (191R396) were activated by dexamethasone in Cry-deficient cells than in controls, indicating that Cry limits induction of a larger network of glucocorticoid receptor responsive genes. Perhaps even more unexpectedly, of 657 dexamethasone-repressed genes only 64 were suppressed in DKO cells (Fig. 2b) . We confirmed the observed expression patterns for several individual genes in an independently derived pair of control and cryptochrome-deficient mouse embryonic fibroblasts (MEFs) ( Fig. 2c ). Because the interpretation of the results for individual transcripts is complicated by the potential role of circadian synchronization, we also examined the expression profile of the established glucocorticoid receptor transcriptional target serum/glucocorticoid regulated kinase 1 (sgk1) in response to dexamethasone stimulation. We found that sgk1 messenger RNA (mRNA) is more robustly activated in cry1 2/2 ;cry2 2/2 cells than control cells within 2 h of exposure to glucocorticoids ( Fig. 2d ) and over a range of dosages ( Fig. 2e ). In general, the dynamic response to dexamethasone is complex and transcript dependent but more positive in the absence of cryptochromes ( Supplementary Fig. 2 ). Together, these results lead to the surprising suggestion that Cry1 and Cry2, central regulators of the circadian clock, also directly oppose dexamethasone-induced glucocorticoid receptor activation. 
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Some of the best-studied physiological roles of glucocorticoids are suppression of the immune system and activation of gluconeogenesis. We examined whether cryptochromes are required for transrepression of inflammatory genes in primary bone marrow macrophages from wild-type and DKO mice. After lipopolysaccharide stimulation with or without previous dexamethasone treatment, the expression of tumour-necrosis factor alpha (TNF-a) and chemokine (C-C motif) ligand 4 (Ccl4) was indistinguishable in wild-type and DKO macrophages ( Supplementary Fig. 3 ). The basal and lipopolysaccharideinduced expression of monocyte chemoattractant protein 1, interleukin 6 and inducible nitric oxide sythase was elevated in macrophages lacking Cry1 and Cry2, but these transcripts were equally suppressed by dexamethasone treatment regardless of the presence or absence of cryptochromes ( Supplementary Fig. 3 ). Thus, cryptochromes appear to regulate a distinct, albeit substantial, subset of glucocorticoid receptor regulated target genes, which does not include the NF-kB inflammatory gene network.
Chronic treatment with gluocorticoids to suppress inflammation often results in hyperglycaemia due to glucocorticoid-receptorinduced expression of phosphoenolpyruvate carboxykinase 1 (Pck1), a rate-limiting gluconeogenic enzyme in the liver. If cryptochrome repression of glucocorticoid-receptor-mediated transcription were relevant in the liver, we would expect the ability of glucocorticoids to induce pck1 transcription to be lower when cryptochromes are present. Indeed, pck1 induction after a 1 h exposure to dexamethasone was dependent on the time of day and the induction of pck1 is inversely correlated with the amount of cryptochrome protein in the nucleus (Fig. 3a) . Excluding the possibility that the observed effect of day-time involves altered expression or chromatin accessibility of glucocorticoid receptor, in an independent experiment, we observed a greater increase in pck1 expression in response to dexamethasone at ZT4 (zeitgeber time, which denotes hours after the lights are turned on) than at ZT16, even though the glucocorticoid-induced association of glucocorticoid receptor with the Pck1 promoter was relatively elevated at ZT16 ( Supplementary Fig. 4 ). Furthermore, using antibodies that we generated to detect endogenous Cry1 and Cry2 ( Supplementary Fig. 5 ), we found that cryptochromes interact with glucocorticoid receptor in the liver after ligand stimulation in vivo at night (ZT18) when glucocoticoids are less effective at inducing the expression of pck1 (Fig. 3b ). (Cry1 2/2 and Cry2 2/2 samples were used in this experiment to ensure antibody specificity without abolishing circadian rhythmicity.) Strikingly, dexamethasone stimulated pck1 transcription 12.8-fold at ZT16 in Cry-deficient livers, even though glucocorticoid-induced association of glucocorticoid receptor with the Pck1 promoter was reduced in the DKO livers (Fig. 3c ). Finally, chromatin immunoprecipitation of Cry1 and Cry2 revealed that cryptochromes are associated with the Pck1 promoter GRE after treatment with dexamethasone in vivo in mouse livers, whereas dexamethasone had no effect on the Bmal1-mediated association of Cry1 and Cry2 with the Dbp promoter ( Fig. 3d ). Together, these data demonstrate that cryptochromes directly repress glucocorticoid receptor induction of pck1 in the liver and thus may limit glucocorticoid-induced hyperglycaemia.
To examine the role of cryptochromes in glucocorticoid-dependent physiology, we measured several glucocorticoid-receptor-dependent parameters in wild-type and Cry-deficient mice. (Importantly, Crydeficient mice were maintained in 12:12 light:dark conditions and were found to have normal behavioural patterns, Supplementary  Fig. 6 .) In addition to suppressing inflammation and increasing gluconeogenesis through pck1, a principal role of glucocorticoids is to promote negative feedback in all three organs of the (HPA) axis 19 . However, in DKO mice, we find that glucocorticoids, which normally show robust cycling rhythm, fail to be suppressed during the day as they are in wild-type mice (Fig. 4a) . Perhaps not surprisingly, glucose homeostasis is severely disrupted in Cry-deficient mice, consistent with the observed regulation of pck1 transcription: thus, DKO mice exhibit elevated blood glucose in response to acute feeding after an overnight fast ( Fig. 4b) and severely impaired glucose clearance in a glucose tolerance test (Fig. 4c ). Even mice lacking either Cry1 (cry1 2/2 ) or Cry2 (cry2 2/2 ) were significantly impaired in their ability to restore normal blood glucose after glucose injection (Fig. 4c) . In contrast, Cry-deficient animals were normally responsive to insulin (Fig. 4d) .
To examine directly the role of cryptochromes in repression of the HPA axis and in glucocorticoid-induced hyperglycaemia, we subjected wild-type and littermate DKO mice to 8 weeks of chronic glucocorticoid treatment. After long-term exposure to dexamethasone, endogenous production of corticosterone was completely shut down in wildtype mice as expected, and was incompletely suppressed in Crydeficient mice (Fig. 4e ), suggesting that cryptochromes directly participate in glucocorticoid-receptor-mediated repression of glucocorticoid synthesis through the HPA axis. Furthermore, circulating adrenocorticotropic hormone (ACTH) seems to be elevated in DKO mice ( Supplementary Fig. 7 ), suggesting that cryptochromes may regulate steroidogenesis upstream of pituitary secretion of ACTH. Chronic glucocorticoid treatment caused significant fasting hyperglycaemia both in wild-type and DKO mice, but it was more severe in mice lacking cryptochromes (Fig. 4f ). In addition, Cry-deficient mice exposed to chronic glucocorticoid treatment exhibited greater glucose intolerance than Cry-deficient mice treated with saline for the same time period, whereas wild-type mice had the same ability to respond to a mild glucose challenge whether they were exposed to saline or dexamethasone over the 8 weeks of treatment (Fig. 4g ). Together, these data suggest that cryptochrome repression of glucocorticoid-receptor-mediated transcription is an important mechanism by which circadian clocks modulate metabolic physiology in vivo.
It has become increasingly clear that circadian clocks play an important role in optimizing the temporal coordination of tissue 
and subsequent oscillations in insulin, glucagon and other hormones 20 ; they may also be modulated by circadian repressors in the period and cryptochrome families.
In this study, we describe an interaction between cryptochromes and the glucocorticoid receptor, through which Cry1 and Cry2 repress glucocorticoid-receptor-dependent transcription, including the induction of pck1 in the liver ( Supplementary Fig. 1 ). We demonstrate that Cry1 and Cry2 interact with glucocorticoid receptor in mouse liver and are associated with a GRE in the Pck1 promoter in a glucocorticoid-dependent manner. The physiological relevance of these associations is apparent in the increased susceptibility of cryptochrome-deficient mice to glucocorticoid-induced hyperglycaemia. Notably, cry1 2/2 , cry2 2/2 and cry1 2/2 ;cry2 2/2 mice were also strikingly intolerant of a high dose of glucose, even in the absence of supplemental glucocorticoid treatment. This reflects a combination of increased glucocorticoid production, increased glucocorticoidinduced pck1 transcription and other cryptochrome-dependent pathways, including both Clock/Bmal1-dependent transcriptional programs and recently reported Cry-dependent effects on cyclic AMP (cAMP)-responsive element-binding protein (CREB)-mediated transcription 21 . Past studies have indicated a role for PER2 upregulation in the hyperglycaemia induced by glucocorticoids through glucocorticoid receptor binding a GRE in the Per2 promoter 22 ; we have found a distinct regulatory axis, involving direct physical association between cryptochormes and glucocorticoid receptor, by which circadian clocks modulate the response to glucocorticoids.
In addition, we found that Cry1 and Cry2 participate in glucocorticoiddependent suppression of the HPA axis and the production of endogenous glucocorticoids. The observed effects on corticosterone production are reminiscent of a recent study in which cry1 2/2 ;cry2 2/2 mice were found to have constitutively elevated production of aldosterone owing to adrenal de-repression of type VI 3-b hydroxylsteroid dehydrogenase (hsd3b6) 23 . Combined with our observation of direct interactions between cryptochromes and multiple steroid hormone receptors ( Fig. 1a and data not shown), these data suggest that cryptochromes may play a general role in feedback inhibition of steroid hormone biosynthesis. However, the anatomic location of action may differ as previous studies did not observe a role of cryptochromes in corticosteroid biosynthetic gene expression in adrenal cortex, although they do seem to modulate aldosteronesynthesizing pathways in the adrenal gland 23 .
These results suggest a specific mechanism through which cryptochromes couple the activity of clock and receptor target genes to complex genomic circuits underpinning normal metabolic homeostasis. Although we found that cryptochromes participate in glucocorticoid regulation of gluconeogenesis and steroidogenesis, they are not required for trans-repression of inflammatory gene transcription. Thus, the undesirable metabolic side effects of glucocorticoids used to suppress inflammation may be alleviated by altering the timing of treatment or by combining them with agents that can stabilize Cry1 and/or Cry2 in the liver. As metabolic syndrome is a complex blend of chronic inflammation and poorly controlled glucose homeostasis, the ability of cryptochromes to integrate metabolism and circadian rhythms suggests that targeting the glucocorticoid receptor/Cry interface could be a new therapeutic strategy.
METHODS SUMMARY
The Methods section provides detailed information about all experimental procedures including (1) the generation, culture and transfection of cell lines, (2) generation or sources of plasmids and antibodies, (3) luciferase assays, (4) preparation of samples for western blotting, immunoprecipitation and chromatin immunoprecipitation, (5) performance and analysis of microarray experiments, (6) quantitative PCR, (7) analysis of behaviour and metabolism in mice, (8) measurement of ACTH and corticosterone by immunoassay and (9) acute and chronic treatment of mice with synthetic glucocorticoids.
